Advanced Biomarker Profiling
Evaluation of a defined molecular biomarker profile.
Loading page
SeroMark-1 is an advanced blood-based biomarker test designed to provide additional information for prostate cancer risk assessment, helping doctors make more informed decisions about the next step.
For men discussing prostate cancer risk with a healthcare professional · Complements PSA · Doctor interpretation required
Indian study population
Additional insight for the next clinical decision.
Prostate cancer risk assessment can involve more than one clinical factor. SeroMark-1 brings additional biomarker-based molecular information into the conversation, helping individuals and healthcare professionals explore prostate cancer risk with a broader perspective.
By evaluating a biomarker profile, our approach is designed to generate a broader layer of molecular information for prostate cancer risk assessment.
Evaluation of a defined molecular biomarker profile.
Specialised laboratory analysis designed to generate reliable molecular information.
Analytical methods used to evaluate complex biomarker patterns.
Information designed to support interpretation within an appropriate clinical setting.
SeroMark-1 does not replace PSA or diagnose cancer. It is designed to add molecular information that a qualified healthcare professional can consider with your history, examination, PSA, and any other appropriate investigations.
A PSA value can be influenced by several prostate conditions. SeroMark-1 is designed to add a separate molecular perspective for doctor-guided review.
The test evaluates a profile of serum phospholipid biomarkers rather than relying on one biomarker signal alone.
Low, borderline, and elevated risk bands help structure the discussion about whether routine follow-up or further evaluation may be appropriate.
Patient guidance stays simple and practical. Scientific and workflow detail is available separately for doctors and healthcare professionals.
Learn who may consider SeroMark-1, how to prepare, what the risk bands mean, and how to request collection support.
Open the patient guideExplore the multi-biomarker approach, intended clinical role, workflow, result bands, limitations, and diagnostic enquiry route.
Open the doctor guideThe result translates a panel of serum biomarker signals into a structured index that a qualified doctor interprets alongside your history and other findings.
Low risk band
Low0.00–0.34
Borderline0.35–0.49
Elevated0.50–1.00
Demonstration only. A healthcare professional must interpret every result in its full clinical context.
A controlled pathway from fasting serum collection through quality checks, predictive analysis, reporting, and doctor review.
A fasting blood sample is collected and the serum is shipped to the laboratory for analysis.
The laboratory checks the sample against quality-control parameters and processes the data through the bioinformatics pipeline.
The report is released electronically or in hard copy for interpretation and follow-up with a doctor.
In the Indian study population identified in Nutech's approved material, the multi-protein SeroMark-1 panel reported higher values across these measured performance metrics.
Study-population results do not guarantee an individual outcome. SeroMark-1 remains a screening aid and does not replace PSA, examination, imaging, biopsy, or doctor judgement.
| Performance metric | PSA test | SeroMark-1 |
|---|---|---|
| Sensitivity | 62.0% | 79.7% |
| Specificity | 70.0% | 87.9% |
| Overall classification accuracy | 65.0% | 83.6% |
| ROC AUC | 0.71 | 0.927 |
Nutech combines clinical-performance evidence, objective predictive analytics, more than a decade of biomarker experience, and nationwide sample coordination.
Robust performance reported in the Indian study population.
Multivariate analytics for consistent risk classification.
Sample coordination supported across India.
Check the screening criteria, find a collection location, or speak with the Nutech team before you decide.